Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Income from Continuing Operations (2018 - 2025)

Neurogene (NGNE) has disclosed Income from Continuing Operations for 5 consecutive years, with 20981000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 3.15% year-over-year to 20981000.0, compared with a TTM value of 86172000.0 through Sep 2025, down 47.85%, and an annual FY2024 reading of 74150000.0, down 40.81% over the prior year.
  • Income from Continuing Operations was 20981000.0 for Q3 2025 at Neurogene, up from 23154000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 17061000.0 in Q1 2024 and bottomed at 23154000.0 in Q2 2025.